Alzheimer’s Disease Diagnostic Market to Grow at 12.8% CAGR, Reaching US$10.25 Billion by 2032

Key Highlights

The Alzheimer’s Disease Diagnostic Market is being reshaped by disease burden and technology. The report cites about 50 million people worldwide living with Alzheimer’s disease and dementia in 2022 and an estimate of 152 million by 2050, creating sustained demand for scalable diagnosis.

CSF testing leads the diagnosis segment, while cholinesterase inhibitors lead therapeutics. North America is expected to hold the largest regional share at 39.5%.

Why This Market Matters Now

The Alzheimer’s Disease Diagnostic Market matters because treatment pathways increasingly need stronger biomarker evidence. Blood tests, CSF biomarkers and PET imaging give clinicians more ways to identify pathology and determine when specialist assessment is needed.

View Sample Report: https://www.maximizemarketresearch.com/request-sample/116921/

That change also reshapes spending priorities. Laboratories need validated biomarker platforms, imaging providers need quantitative tools, and drug developers need diagnostics that can help select and monitor patients. Lengthy clinical trials, approval processes, high investment requirements and failure risk remain barriers.

Market Overview

The Alzheimer’s Disease Diagnostic Market is forecast to grow from US$4.41 billion in 2025 to nearly US$10.25 billion by 2032 at a CAGR of 12.8%. The report identifies dementia prevalence, biomarker investment, drug pipelines, treatment options and sophisticated early-detection diagnostics as key growth drivers.

Alzheimer’s disease is a progressive form of dementia affecting memory, thought, language and interaction. The report states that no cure is available, while medicines can temporarily reduce symptoms, keeping diagnosis central to treatment planning and follow-up.

Growth Drivers & Healthcare Trends

Alzheimer’s Disease Diagnostic Market growth is increasingly linked to biomarker-led care. Government initiatives, medical institutions and academic centres are investing in research and pathological studies, while new techniques and regulatory approvals expand available diagnostic tools.

Digital imaging remains important. CT and MRI help rule out other causes of dementia, while the report says brain imaging is gaining wider acceptance through digital scanning. In March 2026, the Alzheimer’s Drug Discovery Foundation added US$50 million to Phase 3 of its Diagnostics Accelerator, bringing total investment to US$150 million for next-generation biomarkers and AI tools targeting tau pathology, ageing mechanisms and co-pathologies.

Segment Insights

Within the Alzheimer’s Disease Diagnostic Market, CSF testing dominates diagnosis. CSF amyloid-beta, total tau and phosphorylated tau can help distinguish Alzheimer’s disease and support assessment of progression from mild cognitive impairment to dementia.

Cholinesterase inhibitors are expected to hold the largest therapeutics share because of their role in managing symptoms involving memory, thinking, language and judgement. The public report does not identify a fastest-growing diagnostic or therapeutic segment, so no unsupported ranking is assigned.

View Sample Report: https://www.maximizemarketresearch.com/request-sample/116921/

UK & Global Regional Outlook

For UK healthcare stakeholders, the Alzheimer’s Disease Diagnostic Market report includes the UK within European analysis but publishes no standalone UK market size, CAGR or share. The most relevant European signal is biomarker adoption: C2N Diagnostics launched the PrecivityAD blood test in Europe after approval, using mass spectrometry to support Alzheimer’s diagnosis.

North America leads the Alzheimer’s Disease Diagnostic Market with a 39.5% share in the forecast period. The US is identified as the leading North American country, and the report cites around 144 active US clinical trials in Alzheimer’s diagnosis.

Germany, China, Japan, India and South Korea are included in the report’s country-level scope, but no separate public-page statistics are disclosed. Country comparisons should therefore avoid unsupported figures.

Competitive Landscape

The Alzheimer’s Disease Diagnostic Market lists Eli Lilly, TauRx, Alector, Accera, Treventis, Neuro-Bio, Cognition Therapeutics, Roche, Novartis, Merck, Pfizer, Allergan and Daiichi Sankyo among key players.

Competition is broadening beyond traditional therapeutics. Companies with less-invasive blood tests can compete on access and convenience, while imaging suppliers can differentiate through quantitative monitoring. The commercial opportunity lies in linking diagnosis more directly with treatment selection and follow-up.

Recent Developments

Recent activity in the Alzheimer’s Disease Diagnostic Market shows regulation moving towards blood-based biomarkers and treatment monitoring. In May 2025, the FDA cleared Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, described by the report as the first in-vitro diagnostic blood test cleared to aid Alzheimer’s diagnosis.

In June 2025, the FDA expanded Vizamyl PET imaging approval to include quantitative amyloid measurement and treatment monitoring. Roche followed in October 2025 with clearance for the Elecsys pTau181 plasma test for primary-care use; the report states a 97.9% negative predictive value.

View Sample Report: https://www.maximizemarketresearch.com/request-sample/65267/

Strategic Opportunities

Investment opportunities in the Alzheimer’s Disease Diagnostic Market are moving towards scalable biomarker platforms, blood testing, quantitative imaging and AI-supported research. Less-invasive diagnostics can widen screening access, while monitoring tools can gain value as anti-amyloid treatment increases the need for objective measurement.

The source does not publish reimbursement developments or quantified precision-medicine adoption. Commercial strategy should therefore focus on documented drivers: diagnostic accessibility, regulatory clearance, clinical evidence and research investment.

Future Outlook

The Alzheimer’s Disease Diagnostic Market is positioned for strong expansion through 2032 as dementia burden meets faster diagnostic innovation. The 12.8% market forecast favours companies able to translate biomarker science into practical tools for primary care, laboratories and specialist neurological pathways.

Blood testing may reduce dependence on invasive CSF sampling or expensive PET imaging for some assessment steps, while imaging remains important for treatment monitoring. Clinical validation, regulatory execution and earlier diagnosis will shape competitive advantage.

Explore Similar Reports

Global ADHD Therapeutics Market 

Global Klinefelter Syndrome treatment Market 

Global Nephrology Devices Market 

Analyst Perspective Komal Patil

The supplied MMR report page does not contain an attributable quotation from Komal Patil. To comply with the source-only requirement, no quotation has been invented or attributed.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

Contact Us

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com